title: Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.
abstract: OBJECTIVE
  Cisplatin-based combination chemotherapy is the mainstay of treatment for advanced bladder cancer. However, full doses of cisplatin cannot be delivered in patients with impaired renal function. Our aim was to prove the feasibility of a gemcitabine and low-dose cisplatin regimen, delivered every two weeks in patients with impaired renal function.
  
  
  METHODS
  Patients with locally advanced or metastatic bladder cancer with creatinine clearance between 35-60 ml/min received gemcitabine 2500 mg/m2 and cisplatin 35 mg/m2 on day 1, every 14 days.
  
  
  RESULTS
  Between January 2004 and March 2005, 17 patients were treated. Mean creatinine clearance was 47.8 ml/min (range: 37-59 ml/min). Four patients had previously received chemotherapy with gemcitabine and/ or platinum. Median number of cycles per patient was 5 (1-13). No patient developed renal toxicity or worsening of renal function. Main toxicities were (grade 3/4): Anemia 2/1; leucopenia: 1/2; trombopenia 1/1. There was one toxic death related to metabolic acidosis, secondary to vomiting. Among 16 patients evaluable for response, we observed one complete response, 7 partial responses (ORR: 53.3%; IC 95%: 28.1-78.5%), 6 stabilizations (37.5%) and 2 progressions (12.5%).
  
  
  CONCLUSIONS
  Gemcitabine and low-dose cisplatin is a safe and feasible combination in patients with poor renal function. Response rates seem similar to those previously described with standard schedules of this combination.
authors.affiliation: Oncology Department. Hospital del Mar, URTEC, Universitat Autónoma de Barcelona, Spain. jcarles@imas.imim.es
authors.forename: Joan
authors.initials: J
authors.lastname: Carles
authors.forename: Cristina
authors.initials: C
authors.lastname: Suárez
authors.forename: Carlos
authors.initials: C
authors.lastname: Mesía
authors.forename: Miquel
authors.initials: M
authors.lastname: Nogué
authors.forename: Albert
authors.initials: A
authors.lastname: Font
authors.forename: Montserrat
authors.initials: M
authors.lastname: Doménech
authors.forename: Marta
authors.initials: M
authors.lastname: Suárez
authors.forename: Ignasi
authors.initials: I
authors.lastname: Tusquets
authors.forename: M
authors.initials: M
authors.lastname: Gallén
authors.forename: Joan
authors.initials: J
authors.lastname: Albanell
authors.forename: Xavier
authors.initials: X
authors.lastname: Fabregat
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003404:Creatinine / Q000097:blood*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D017567:Karnofsky Performance Status; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D013997:Time Factors; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D003841:Deoxycytidine; D003404:Creatinine; D002945:Cisplatin; D000093542:Gemcitabine